CLR 131: Additional Phase I data

Data from 4 evaluable patients with relapsed or refractory MM in the second cohort of an open-label, dose-escalation, U.S. Phase I trial showed that a single 18.75 mCi/m2 dose of IV CLR 131 with or wi...